Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 390

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 390
---
 adjournment of the special meeting to a later date or dates to the extent necessary (i) to ensure that any required supplement or amendment to the proxy statement is provided to BLAC stockholders, (ii) to permit the further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Condition Precedent Proposals, or (iii), if as of the time for which the special meeting is scheduled, the Minimum Available Cash Condition has not been waived by OSR Holdings.” Recommendation of the Board of Directors OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE “FOR” THE ADJOURNMENT PROPOSAL. 238 BUSINESS OF OSR HOLDINGS AND CERTAIN INFORMATION ABOUT OSR HOLDINGS Corporate Overview OSR Holdings is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. We aim to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Our current operating businesses (through our three wholly -ownedsubsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design -augmentedbiologics for age -relatedand other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in Korea. OSR Holdings’ vision is to acquire and operate a portfolio of innovative health -carerelated companies globally. Corporate Strategy As a global healthcare holding company, with operations in South Korea and Switzerland and an office in the United States, we are not limited by geographic boundaries. We intend to leverage our existing and expanding network of academic and industry leaders and investor network, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research. Subsidiary candidates are companies that are either already existing entities or new companies formed in connection with acquiring or licensing existing assets from pharmaceutical firms. We expect to attract industry partners either as co -investorsor through technology licensing deals and may raise capital directly from private, strategic or public investors. We seek to chart a potentially more efficient and optimal route by pairing what we believe are the right team and pharmaceutical or medical device technologies that have the potential to treat diseases and improve healthcare outcomes with the necessary financial and other resources. Since our target markets feature large established global businesses with abundant capital that acquire healthcare companies, we hope to realize additional liquidity through the